Transocean Ltd.
Total Consideration
$5.80B
Valaris Limited — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$14
Book Value Per Share
$45
Free Cash Flow Per Share
$3
Cash Per Share
$8
Revenue Per Share
$33
OCF Per Share
$8
Return on Equity
36.3%
Return on Assets
20.2%
Return on Invested Capital
12.6%
Debt to Equity
0.34
Current Ratio
1.77
Quick Ratio
1.77
Asset Turnover
0.49
Days Payables Outstanding
77.99
Days Inventory On Hand
—
SBC / Revenue
1.1%
Capex / Revenue
14.5%
Working Capital
$534M
Net Current Asset Value
$-908M
Invested Capital
$4.26B
OCF / Net Income
0.56
FCF / Net Income
0.21
Accruals Ratio (Sloan)
8.2%
Net Debt
$487M
Net Debt / EBITDA
0.78
Interest Coverage
—
Cash Coverage
—
Dividend Coverage
—
Capex Coverage
1.59
Tangible Common Equity
$3.17B
TCE / Total Assets
59.7%
Goodwill / Total Assets
—
NOPAT
$477M
Cash ROIC
5.4%
WC / Revenue
22.5%
Capex / D&A
2.35
Reinvestment Rate
41.3%
Total Payout Ratio
10.2%
Asset Growth vs Revenue Growth
19.8%
Revenue 5Y CAGR
2.9%
EPS 5Y CAGR
—
FCF 5Y CAGR
—
EBITDA 5Y CAGR
14.3%
Book Value 5Y CAGR
-19.4%
Stock Price (FY-end)
$50
Market Cap
$3.57B
P/E Ratio
3.64
P/S Ratio
1.51
P/B Ratio
1.13
P/TB Ratio
1.13
P/OCF Ratio
6.54
P/FCF Ratio
17.63
Enterprise Value
$4.06B
EV / EBITDA
6.51
EV / Sales
1.71
EV / FCF
20.03
FCF Yield
5.7%
Shareholder Yield
2.1%
Buyback Yield
2.8%
Capex Yield
9.6%
Dividend Per Share
—
DPS YoY Growth
—
Operating Leverage
130.67
Graham Number
$118
Shares Variation (YoY)
-2.7%
Beta (5Y)
1.14
Cost of Equity
10.2%
Cost of Debt (after tax)
—
52W High
$60
52W Low
$29
Trailing Return 1Y
22.8%
F-Score (Piotroski)
7.00
Z-Score (Altman)
2.50
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
Valaris Limited — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2019 | FY2020 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 19.00% | 19.00% | 0.00% | 0.00% | 0.00% | 15.00% |
| State & Local Income Taxes | — | — | — | — | — | — |
| Foreign Rate Differential | -2.81% | -2.80% | 0.00% | — | — | — |
| Other Adjustments | 7.60% | -1.30% | 2.80% | 0.00% | 0.00% | — |
| Valuation Allowance Change | -145.10% | -1.50% | 0.60% | -9.54% | -2.30% | 2.90% |
| Tax Law Change | -21.60% | 2.40% | 0.00% | — | — | — |
| Effective Tax Rate | -2.01% | 5.10% | 19.20% | -9.29% | 0.10% | -77.30% |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $128.4M | −$259.4M | $43.1M | −$782.6M | $400.0K | −$426.8M |
| Income Taxes Paid (Cash) | — | $48.5M | $5.6M | −$8.3M | $55.6M | $61.5M |
Valaris Limited — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.